Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong

Wu, David Bin-Chia; Yee, Chi Hang; Ng, Chi‐Fai; Lee, Shaun Wen Huey; Chaiyakunapruk, Nathorn; Chang, Yih Hsin; Lee, Kenneth Kwing Chin

doi:10.3389/fphar.2018.01078

Cited by 4 publications

(2 citation statements)

References 29 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Potential reasons for these discrepancies include the evaluations of the economic costs of cancer, which can vary across countries and settings based on local disease burden, healthcare resources availability, access to care utilization and outcomes data, as well as healthcare practices [ 15 – 17 ]. Currently, little is known about the economic impact of introducing olaparib maintenance therapy for women with ovarian cancer in Malaysia.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia

Yong,

Yehgambaram,

Lee

2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Introduction Ovarian cancer is one of the most common cancer among women in Malaysia. Patients with ovarian cancer are often diagnosed at an advanced stage. Despite initial response to surgery and chemotherapy, most patients will experience a relapse. Olaparib has been reported have promising effects among BRCA mutated ovarian cancer patients. This study aimed to evaluate the cost–effectiveness of olaparib as a maintenance therapy for BRCA ovarian cancer in Malaysia. Methods We developed a four-state partitioned survival model which compared treatment with olaparib versus routine surveillance (RS) from a Malaysian healthcare perspective. Mature overall survival (OS) data from the SOLO-1 study were used and extrapolated using parametric models. Medication costs and healthcare resource usage costs were derived from local inputs and publications. Deterministic and probabilistic sensitivity analyses (PSA) were performed to explore uncertainties. Results In Malaysia, treating patients with olaparib was found to be more costly compared to RS, with an incremental cost of RM149,858 (USD 33,213). Patients treated with olaparib increased life years by 3.05 years and increased quality adjusted life years (QALY) by 2.76 (9.45 years vs 6.40 years; 7.62 vs 4.86 QALY). This translated to an incremental cost-effectiveness ratio (ICER) of RM 49,159 (USD10,895) per life year gained and RM54,357 (USD 12,047) per QALY gained, respectively. ICERs were most sensitive to time horizon of treatment, discount rate for outcomes, cost of treatment and health state costs, but was above the RM53,770/QALY threshold. Conclusion The use of olaparib is currently not a cost-effective strategy compared to routine surveillance based upon the current price in Malaysia for people with ovarian cancer with BRCA mutation, despite the improvement in overall survival.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia

Yong,

Yehgambaram,

Lee

2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…Benign prostatic obstruction (BPO) affects a fourth of men in their lifetime and begets a considerable economic burden to the healthcare system [ 1 2 ]. If refractory to medical treatment, surgical intervention is offered based on prostate size.…”

Section: Introductionmentioning

confidence: 99%

Aquablation for benign prostatic obstruction: Single center technique evolution and experience

et al. 2021

View full text Add to dashboard Cite

Purpose Aquablation is a new technology that relies on real-time ultrasound guidance to ablate prostatic tissues using high velocity pressurized water. We hereby present our data and experience in this technique by exploring the perioperative surgical and functional outcomes. Materials and Methods This is a prospectively filled study including consecutive patients who underwent aquablation at our Middle Eastern tertiary care center. Patient demographics, voiding parameters, and prostate disease specific variables were collected. We reported on the surgical and functional outcomes as well as the 3-month adverse events. We also explored the trend in hemoglobin drop and hemostasis method by dividing the consecutive cases into four temporal periods. Results Fifty-nine patients underwent aquablation between March 2018 and March 2020. Mean time from transrectal ultrasound to Foley insertion was 48.5±2.5 minutes. Cautery was performed in 35 patients (59.3%) and a catheter-tensioning device was mounted in 50 patients (84.7%). On average, the hemoglobin dropped by −1.7±0.2 ng/dL (p<0.0001). The average length of catheterization and hospital stay were 2.1±0.3 days and 2.2±0.1 days, respectively. Only three patients (5.1%) were re-hospitalized. At three months, the average drop in serum prostate-specific antigen was −36.6±6.0% (p<0.0001) and functional outcomes considerably improved. We also recorded 14 adverse events in 13 patients (overall rate of 22.0%), with grade 1 and grade 2 complications comprising 71.4% of all adverse events. Conclusions Our study results confirm the safety and efficacy of the aquablation procedure in the adoption phase.

show abstract

Exploring pharmacological interventions in benign prostate hyperplasia: the role of cost-effectiveness analysis in daily practice and future directions

Almusafer,

Narayan,

Nnorom

et al. 2024

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong

Cited by 4 publications

References 29 publications

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia

Aquablation for benign prostatic obstruction: Single center technique evolution and experience

Exploring pharmacological interventions in benign prostate hyperplasia: the role of cost-effectiveness analysis in daily practice and future directions

Contact Info

Product

Resources

About